Author

D. Plana

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Assay:clinical cohort / trial· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

A. C. Palmer· 3 shared P. K. Sorger· 2 shared A. Loo· 1 shared A. Mehta· 1 shared A. Shi· 1 shared B. M. Alexander· 1 shared C. Bullock· 1 shared C. Kowal· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. C. Palmer

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer patient survival can be accurately parameterized, revealing time-dependent therapeutic effects and doubling the precision of small trials

D. Plana, G. Fell, B. M. Alexander, A. C. Palmer, P. K. Sorger

The paper imputes survival data from oncology trials and shows that using Weibull distributions improves trial precision and reveals time-dependent therapeutic effects in immune checkpoint inhibitor trials.

bioRxiv · May 14, 2021Cancer Biology

Comparing the efficacy of cancer therapies between subgroups in basket trials

A. C. Palmer, D. Plana, P. Sorger

This paper uses permutation testing to compare cancer therapy efficacy across subgroups in basket trials, identifying missed therapeutic benefits in specific mutations.

bioRxiv · Jan 14, 2020Cancer Biology

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts

A. C. Palmer, D. Plana, H. Gao, J. M. Korn, G. Yang, J. Green, X. Zhang, R. Velazquez, M. E. McLaughlin, D. A. Ruddy, C. Kowal, J. Goldovitz, C. Bullock, S. Rivera, D. Rakiec, , J. A. Williams

This study identifies biomarker-guided treatment strategies for ovarian cancer using patient-derived tumor xenografts, finding that nearly 90% of PDXs responded to at least one targeted therapy.

bioRxiv · Jan 8, 2020Cancer Biology

Plasma-derived exosomal analysis and deconvolution enables prediction and tracking of melanoma checkpoint blockade response

A. Shi, G. G. Kasumova, W. A. Michaud, J. Cintolo-Gonzalez, J. F. Ohmura, A. Mehta, I. Chien, D. T. Frederick, S. Cohen, D. Plana, D. Johnson, K. T. Flaherty, R. J. Sullivan, M. Kellis, G. M. Boland

This paper uses plasma-derived exosomal RNA to predict and track melanoma response to immune checkpoint inhibitors by analyzing tumor and immune signatures.

bioRxiv · Oct 18, 2019 · PreprintCancer Biology